Most emetogenic anticancer drug is:
**Core Concept**
The question is testing the knowledge of the emetogenic potential of various anticancer drugs, which is a crucial aspect of chemotherapy-induced nausea and vomiting (CINV). Emetogenic potential refers to the likelihood of a drug to cause nausea and vomiting.
**Why the Correct Answer is Right**
The correct answer is **Cisplatin**, which is a platinum-based chemotherapeutic agent used to treat various types of cancers, including testicular, ovarian, lung, bladder, and stomach cancers. Cisplatin is known for its high emetogenic potential, particularly when used in combination with other chemotherapy agents. The mechanism behind cisplatin-induced emesis involves the release of substance P, a neurotransmitter that stimulates the vomiting center in the brain. Cisplatin also causes damage to the chemoreceptor trigger zone (CTZ) and the vomiting center in the central nervous system, leading to nausea and vomiting.
**Why Each Wrong Option is Incorrect**
**Option A:** **Doxorubicin** is an anthracycline antibiotic that intercalates DNA strands, inhibiting the synthesis of nucleic acids. While doxorubicin is associated with cardiotoxicity and myelosuppression, it is not the most emetogenic anticancer drug.
**Option B:** **Paclitaxel** is a taxane that stabilizes microtubules, preventing cell division. Paclitaxel is associated with neurotoxicity and myelosuppression but is not the most emetogenic anticancer drug.
**Option D:** **Etoposide** is a topoisomerase inhibitor that intercalates DNA strands, preventing the unwinding of DNA during replication. Etoposide is associated with myelosuppression and hepatotoxicity but is not the most emetogenic anticancer drug.
**Clinical Pearl / High-Yield Fact**
The 5-HT3 receptor antagonists, such as ondansetron, are effective in preventing CINV, particularly in patients receiving highly emetogenic chemotherapy agents like cisplatin. A well-timed dose of ondansetron can significantly reduce the incidence of nausea and vomiting in these patients.
**Correct Answer:** C. Cisplatin.